FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311703170> ?p ?o ?g. }

• W4311703170 abstract "Different forms of vaccines have been developed to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. Several are in widespread use globally. OBJECTIVES: To assess the efficacy and safety of COVID-19 vaccines (as a full primary vaccination series or a booster dose) against SARS-CoV-2.We searched the Cochrane COVID-19 Study Register and the COVID-19 L·OVE platform (last search date 5 November 2021). We also searched the WHO International Clinical Trials Registry Platform, regulatory agency websites, and Retraction Watch.We included randomized controlled trials (RCTs) comparing COVID-19 vaccines to placebo, no vaccine, other active vaccines, or other vaccine schedules.We used standard Cochrane methods. We used GRADE to assess the certainty of evidence for all except immunogenicity outcomes. We synthesized data for each vaccine separately and presented summary effect estimates with 95% confidence intervals (CIs). MAIN RESULTS: We included and analyzed 41 RCTs assessing 12 different vaccines, including homologous and heterologous vaccine schedules and the effect of booster doses. Thirty-two RCTs were multicentre and five were multinational. The sample sizes of RCTs were 60 to 44,325 participants. Participants were aged: 18 years or older in 36 RCTs; 12 years or older in one RCT; 12 to 17 years in two RCTs; and three to 17 years in two RCTs. Twenty-nine RCTs provided results for individuals aged over 60 years, and three RCTs included immunocompromized patients. No trials included pregnant women. Sixteen RCTs had two-month follow-up or less, 20 RCTs had two to six months, and five RCTs had greater than six to 12 months or less. Eighteen reports were based on preplanned interim analyses. Overall risk of bias was low for all outcomes in eight RCTs, while 33 had concerns for at least one outcome. We identified 343 registered RCTs with results not yet available. This abstract reports results for the critical outcomes of confirmed symptomatic COVID-19, severe and critical COVID-19, and serious adverse events only for the 10 WHO-approved vaccines. For remaining outcomes and vaccines, see main text. The evidence for mortality was generally sparse and of low or very low certainty for all WHO-approved vaccines, except AD26.COV2.S (Janssen), which probably reduces the risk of all-cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67; 1 RCT, 43,783 participants; high-certainty evidence). Confirmed symptomatic COVID-19 High-certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer), mRNA-1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP-CorV (Sinopharm-Beijing), and BBV152 (Bharat Biotect) reduce the incidence of symptomatic COVID-19 compared to placebo (vaccine efficacy (VE): BNT162b2: 97.84%, 95% CI 44.25% to 99.92%; 2 RCTs, 44,077 participants; mRNA-1273: 93.20%, 95% CI 91.06% to 94.83%; 2 RCTs, 31,632 participants; ChAdOx1: 70.23%, 95% CI 62.10% to 76.62%; 2 RCTs, 43,390 participants; Ad26.COV2.S: 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; BBIBP-CorV: 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; BBV152: 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants). Moderate-certainty evidence found that NVX-CoV2373 (Novavax) probably reduces the incidence of symptomatic COVID-19 compared to placebo (VE 82.91%, 95% CI 50.49% to 94.10%; 3 RCTs, 42,175 participants). There is low-certainty evidence for CoronaVac (Sinovac) for this outcome (VE 69.81%, 95% CI 12.27% to 89.61%; 2 RCTs, 19,852 participants). Severe or critical COVID-19 High-certainty evidence found that BNT162b2, mRNA-1273, Ad26.COV2.S, and BBV152 result in a large reduction in incidence of severe or critical disease due to COVID-19 compared to placebo (VE: BNT162b2: 95.70%, 95% CI 73.90% to 99.90%; 1 RCT, 46,077 participants; mRNA-1273: 98.20%, 95% CI 92.80% to 99.60%; 1 RCT, 28,451 participants; AD26.COV2.S: 76.30%, 95% CI 57.90% to 87.50%; 1 RCT, 39,058 participants; BBV152: 93.40%, 95% CI 57.10% to 99.80%; 1 RCT, 16,976 participants). Moderate-certainty evidence found that NVX-CoV2373 probably reduces the incidence of severe or critical COVID-19 (VE 100.00%, 95% CI 86.99% to 100.00%; 1 RCT, 25,452 participants). Two trials reported high efficacy of CoronaVac for severe or critical disease with wide CIs, but these results could not be pooled. Serious adverse events (SAEs) mRNA-1273, ChAdOx1 (Oxford-AstraZeneca)/SII-ChAdOx1 (Serum Institute of India), Ad26.COV2.S, and BBV152 probably result in little or no difference in SAEs compared to placebo (RR: mRNA-1273: 0.92, 95% CI 0.78 to 1.08; 2 RCTs, 34,072 participants; ChAdOx1/SII-ChAdOx1: 0.88, 95% CI 0.72 to 1.07; 7 RCTs, 58,182 participants; Ad26.COV2.S: 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants); BBV152: 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants). In each of these, the likely absolute difference in effects was fewer than 5/1000 participants. Evidence for SAEs is uncertain for BNT162b2, CoronaVac, BBIBP-CorV, and NVX-CoV2373 compared to placebo (RR: BNT162b2: 1.30, 95% CI 0.55 to 3.07; 2 RCTs, 46,107 participants; CoronaVac: 0.97, 95% CI 0.62 to 1.51; 4 RCTs, 23,139 participants; BBIBP-CorV: 0.76, 95% CI 0.54 to 1.06; 1 RCT, 26,924 participants; NVX-CoV2373: 0.92, 95% CI 0.74 to 1.14; 4 RCTs, 38,802 participants). For the evaluation of heterologous schedules, booster doses, and efficacy against variants of concern, see main text of review.Compared to placebo, most vaccines reduce, or likely reduce, the proportion of participants with confirmed symptomatic COVID-19, and for some, there is high-certainty evidence that they reduce severe or critical disease. There is probably little or no difference between most vaccines and placebo for serious adverse events. Over 300 registered RCTs are evaluating the efficacy of COVID-19 vaccines, and this review is updated regularly on the COVID-NMA platform (covid-nma.com). Implications for practice Due to the trial exclusions, these results cannot be generalized to pregnant women, individuals with a history of SARS-CoV-2 infection, or immunocompromized people. Most trials had a short follow-up and were conducted before the emergence of variants of concern. Implications for research Future research should evaluate the long-term effect of vaccines, compare different vaccines and vaccine schedules, assess vaccine efficacy and safety in specific populations, and include outcomes such as preventing long COVID-19. Ongoing evaluation of vaccine efficacy and effectiveness against emerging variants of concern is also vital." @default.
• W4311703170 created "2022-12-28" @default.
• W4311703170 creator A5000280447 @default.
• W4311703170 creator A5009796975 @default.
• W4311703170 creator A5011712149 @default.
• W4311703170 creator A5011978339 @default.
• W4311703170 creator A5013765803 @default.
• W4311703170 creator A5017009529 @default.
• W4311703170 creator A5021195498 @default.
• W4311703170 creator A5027839435 @default.
• W4311703170 creator A5029170866 @default.
• W4311703170 creator A5033321113 @default.
• W4311703170 creator A5036345545 @default.
• W4311703170 creator A5037149980 @default.
• W4311703170 creator A5038009611 @default.
• W4311703170 creator A5040036979 @default.
• W4311703170 creator A5040110773 @default.
• W4311703170 creator A5044136372 @default.
• W4311703170 creator A5045420411 @default.
• W4311703170 creator A5050689894 @default.
• W4311703170 creator A5052581893 @default.
• W4311703170 creator A5056473120 @default.
• W4311703170 creator A5057755516 @default.
• W4311703170 creator A5063249733 @default.
• W4311703170 creator A5065028933 @default.
• W4311703170 creator A5066861352 @default.
• W4311703170 creator A5068078908 @default.
• W4311703170 creator A5070817601 @default.
• W4311703170 creator A5071689481 @default.
• W4311703170 creator A5075828719 @default.
• W4311703170 creator A5078390860 @default.
• W4311703170 creator A5090381428 @default.
• W4311703170 date "2022-12-07" @default.
• W4311703170 modified "2023-10-14" @default.
• W4311703170 title "Efficacy and safety of COVID-19 vaccines" @default.
• W4311703170 cites W1973914781 @default.
• W4311703170 cites W2010699829 @default.
• W4311703170 cites W2021622102 @default.
• W4311703170 cites W2027026517 @default.
• W4311703170 cites W2090132603 @default.
• W4311703170 cites W2091808438 @default.
• W4311703170 cites W2131701504 @default.
• W4311703170 cites W2139168999 @default.
• W4311703170 cites W2144034723 @default.
• W4311703170 cites W2144625636 @default.
• W4311703170 cites W2157515759 @default.
• W4311703170 cites W2157823046 @default.
• W4311703170 cites W2169983987 @default.
• W4311703170 cites W2286344981 @default.
• W4311703170 cites W2536224011 @default.
• W4311703170 cites W2560036579 @default.
• W4311703170 cites W2560438049 @default.
• W4311703170 cites W2616456691 @default.
• W4311703170 cites W2741681003 @default.
• W4311703170 cites W2893332348 @default.
• W4311703170 cites W2900898034 @default.
• W4311703170 cites W2943784761 @default.
• W4311703170 cites W2970684805 @default.
• W4311703170 cites W2975424845 @default.
• W4311703170 cites W3006304225 @default.
• W4311703170 cites W3015163167 @default.
• W4311703170 cites W3034858522 @default.
• W4311703170 cites W3042383115 @default.
• W4311703170 cites W3042833857 @default.
• W4311703170 cites W3044336785 @default.
• W4311703170 cites W3048446898 @default.
• W4311703170 cites W3048620154 @default.
• W4311703170 cites W3053491827 @default.
• W4311703170 cites W3081892744 @default.
• W4311703170 cites W3082651931 @default.
• W4311703170 cites W3084707698 @default.
• W4311703170 cites W3088965854 @default.
• W4311703170 cites W3091814234 @default.
• W4311703170 cites W3092766467 @default.
• W4311703170 cites W3092785765 @default.
• W4311703170 cites W3093367571 @default.
• W4311703170 cites W3097110943 @default.
• W4311703170 cites W3100531662 @default.
• W4311703170 cites W3102328262 @default.
• W4311703170 cites W3106869271 @default.
• W4311703170 cites W3108666979 @default.
• W4311703170 cites W3111128314 @default.
• W4311703170 cites W3111255098 @default.
• W4311703170 cites W3111262560 @default.
• W4311703170 cites W3111590711 @default.
• W4311703170 cites W3113774549 @default.
• W4311703170 cites W3118615836 @default.
• W4311703170 cites W3119345685 @default.
• W4311703170 cites W3121691244 @default.
• W4311703170 cites W3127329393 @default.
• W4311703170 cites W3127819257 @default.
• W4311703170 cites W3128702325 @default.
• W4311703170 cites W3128771743 @default.
• W4311703170 cites W3128853581 @default.
• W4311703170 cites W3131762051 @default.
• W4311703170 cites W3133532742 @default.
• W4311703170 cites W3133758295 @default.
• W4311703170 cites W3134141435 @default.
• W4311703170 cites W3135734644 @default.
• W4311703170 cites W3135838854 @default.

• next